GHK-Cu is one of the best studied in this group, and its natural levels tend to decline with age, which can contribute to loss of firmness in the skin and progressive hair thinning
Cyclophosphamide (CTX), ara-C and topotecan (TOP)(CAT) in patients (pts) with refractory or relapsed acute leukemias and transformed chronic myelogenous leukemia (CML)
GHK-Cu influences over 30 percent of human genes, upregulating regenerative pathways while downregulating age-related inflammatory and destructive genes
Chang et al.s review in Current Pharmaceutical Design documents BPC-157s angiogenic mechanisms and systemic tissue protection profile across multiple preclinical models [1]
Subcutaneous injection of 503A compounded GHK-Cu delivers the peptide into circulation, where it can reach target tissues throughout the body, including deeper dermal layers, hair follicles, and any tissue currently in a healing or remodeling phase